

News letter

ALKANTIS, A World's First !

ALKANTIS is pleased to announce the official launch of its world premiere in the U.S.A.

This is an important step that has been taken and will allow Alkantis to confirm its growth towards the globalization of its original concept.

In the U.S.A., and as in many other countries, the idea of introducing a drug-free Patient's Pain Control by using a Sterile dry and sterile cold therapy inside the operating theater (O.R.) was particularly well received.

In the U.S.A., the ASCs (Ambulatory Surgical Centers, day surgery) have shown an immediate interest for better recovery and rehabilitation of the patients.

Our customers have immediately understood that the use of an Alkantis dry and cold therapy which keeps the temperature at skin contact between 41°F (5°C) and 54°F (12°C) is safe for the patients (avoiding burns, frostbites, ...and revascularization issues).



Moreover applying this cold therapy at the right time (directly after surgery) and at the right place (O.R.) helps to control patient's pain better, helps preventing

post surgery complications and helps to respect the hospitalization time.

We are looking to welcome you in the following congresses on the American Surgical booth:

- AORN St Diego, March 4-6, 2013**
Booth N° 3945




- HAS Orlando, March 13-16, 2013**
Booth N° 413



- AAOS Chicago, March 20-22, 2013**
Booth N° Contact us!

AAOS AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS
AMERICAN ASSOCIATION OF ORTHOPAEDIC SURGEONS





It is also important to notice that the use of the Alkantis cold therapy at the O.R. should have a significant impact on reducing the post-operative risks and costs.

- ✓ This has especially caught the attention of the hospital managers who saw potential costs savings:
 - Firstly, to possibly reduce the costs associated with the drugs commonly used to treat the patients' pain.
 - Secondly, to possibly reduce post-surgical complications which results in a reduction of costs (extra hospitalization days,...).
- ✓ Alkantis is more than a product, it is a concept which allows to reduce the costs over a cycle, starting from the surgery until the patient has recovered.
- ✓ In addition to these exclusives performances, Alkantis sterility is particularly relevant for the hygiene services (Infection Control Committees, I.C.C.).
- ✓ As nosocomial transmission are often heavy and expensive, Alkantis acts as a cost-saver and as an effective barrier against cross contamination.
- ✓ A clinical study has been completed demonstrating the proof of the Alkantis Concept.
- ✓ At last but not least, since Alkantis helps treating the patient's pain earlier and in a more comfortable way, it leads to a lower stress factor for patients, therefore benefitting the nursing staff.
- ✓ Finally, as Alkantis is a drug-free therapy, the secondary effects on patients are limited.

Patient's pain control

Analgesics

or

ALKANTIS

	BACK TO THE ROOM	AFTER 6 HOURS
PATIENT'S PAIN		
Groupe Alkantis	90% no pain	70% no pain
Analgesic's injection*	76% no pain	18% no pain
* Oedema		
Drug consumption	Day 1	Day 2
Analgesics reduction	-63%	-43%

CLINICAL STUDY APHP PARIS «HOPITAL JEAN VERDIER» SERVICE PR CHAMPAULT (108 PATIENTS, FROM SEPTEMBER 2010 TO DECEMBER 2011)

INTERNATIONAL CONTACT :

Patrick Caceres
 +33 (0) 620 747 302
p.caceres@alkantis.fr

Jean Claude Riquier
 +33(0) 677 079 747
Jean-claude.riquier@innovcare.net

